Overview of AKR1C3: Inhibitor Achievements and Disease Insights
Yang Liu(China Pharmaceutical University), Haopeng Sun(China Pharmaceutical University), Yijun Liu(Guangdong Medical College), Ying Chen(Xiamen University), Li Zhao(China Pharmaceutical University), Feng Feng(China Pharmaceutical University), Wenyuan Liu(China Pharmaceutical University), Siyu He(ShenZhen People’s Hospital), Qinglong Guo(China Pharmaceutical University)
Cited by 92
Related Papers
Degradation of proteins by PROTACs and other strategies
|Acta Pharmaceutica Sinica B|2019|312
Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease
|European Journal of Medicinal Chemistry|2017|307
MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II
|Human Molecular Genetics|2007|289
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
|Journal of Medicinal Chemistry|2019|270
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
|European Journal of Medicinal Chemistry|2018|200